This study aimed to compare the analgesic effect, patients’ satisfaction, tolerance and hip-joint function recovery by preoperative meloxicam versus postoperative meloxicam in treating hip osteoarthritis (OA) patients receiving total hip arthroplasty (THA). 132 hip OA patients who underwent THA surgery were allocated into postoperative analgesia (POST) and preoperative analgesia (PRE) groups at a 1:1 ratio. In the PRE group, patients took meloxicam 15 mg at 24 h pre-operation, 7.5 mg at 4 h, 24 h, 48 h and 72 h post-operation; in the POST group, patients received meloxicam 15 mg at 4 h post-operation, then 7.5 mg at 24 h, 48 h and 72 h post-operation. Furthermore, postoperative pain, consumption of patient-controlled analgesia (PCA), overall satisfaction and adverse events were evaluated within 96 h post-operation; meanwhile, Harris hip score was assessed within 6 months post-operation. Pain VAS at rest at 6 h, 12 h, 24 h, and pain VAS at passive movement at 6 h, 12 h were decreased in PRE group compared to POST group. In addition, additional consumption of PCA and the total consumption of PCA were both reduced in PRE group compared to POST group. Additionally, overall satisfaction in PRE group was higher at 24 h, 48 h and 72 h compared to POST group. While Harris hip score was of no difference between POST group and PRE group at M3 or M6. Besides, no difference in adverse events incidence was found between the two groups. In conclusion, preoperative meloxicam achieves better efficacy and similar tolerance compared to postoperative meloxicam in hip OA patients post THA.

中文翻译：

---

对于接受全髋关节置换术的髋骨关节炎患者，术前用美洛昔康与术后用美洛昔康进行止痛，患者满意度和功能恢复的随机对照研究。

这项研究旨在比较术前美洛昔康与术后美洛昔康在治疗接受全髋关节置换术（THA）的髋骨关节炎（OA）患者中的镇痛效果，患者满意度，耐受性和髋关节功能恢复。将132例接受THA手术的髋关节OA患者按1：1的比例分为术后镇痛（POST）和术前镇痛（PRE）组。在PRE组中，患者在术前24 h服用美洛昔康15 mg，术后4 h，24 h，48 h和72 h服用7.5 mg；在POST组，患者在术后4 h接受美洛昔康15 mg，然后在术后24 h，48 h和72 h接受7.5 mg。此外，在术后96小时内评估了术后疼痛，消耗患者自控镇痛（PCA），总体满意度和不良事件。与此同时，术后6个月内评估Harris髋关节评分。与POST组相比，PRE组在休息6h，12h，24h时的疼痛VAS和在6h，12h被动运动时的疼痛VAS降低。此外，与POST组相比，PRE组的PCA的额外消耗和PCA的总消耗都减少了。此外，与POST组相比，PRE组在24 h，48 h和72 h的总体满意度更高。在M3或M6时POST组和PRE组的Harris髋关节得分无差异。此外，两组之间不良事件发生率没有差异。总之，与THA术后髋骨OA患者相比，术前美洛昔康与术后美洛昔康相比具有更好的疗效和相似的耐受性。与POST组相比，PRE组在6 h，12 h被动运动时的疼痛VAS降低。此外，与POST组相比，PRE组的PCA的额外消耗和PCA的总消耗都减少了。此外，与POST组相比，PRE组在24 h，48 h和72 h的总体满意度更高。在M3或M6时POST组和PRE组的Harris髋关节得分无差异。此外，两组之间不良事件发生率没有差异。总之，与THA术后髋关节OA患者的术后美洛昔康相比，术前美洛昔康具有更好的疗效和相似的耐受性。与POST组相比，PRE组在6 h，12 h被动运动时的疼痛VAS降低。此外，与POST组相比，PRE组的PCA的额外消耗和PCA的总消耗都减少了。此外，与POST组相比，PRE组在24 h，48 h和72 h的总体满意度更高。在M3或M6时POST组和PRE组的Harris髋关节得分无差异。此外，两组之间不良事件发生率没有差异。总之，与THA术后髋关节OA患者的术后美洛昔康相比，术前美洛昔康具有更好的疗效和相似的耐受性。与POST组相比，PRE组的PCA额外消耗量和PCA的总消耗量均降低。此外，与POST组相比，PRE组在24 h，48 h和72 h的总体满意度更高。在M3或M6时POST组和PRE组的Harris髋关节得分无差异。此外，两组之间不良事件发生率没有差异。总之，与THA术后髋骨OA患者相比，术前美洛昔康与术后美洛昔康相比具有更好的疗效和相似的耐受性。与POST组相比，PRE组的PCA的额外消耗量和PCA的总消耗量均减少。此外，与POST组相比，PRE组在24 h，48 h和72 h的总体满意度更高。在M3或M6时POST组和PRE组的Harris髋关节得分无差异。此外，两组之间不良事件发生率没有差异。总之，与THA术后髋骨OA患者相比，术前美洛昔康与术后美洛昔康相比具有更好的疗效和相似的耐受性。